A US District judge has ruled that a Ohio state law (HB126) that would restrict the use of Cayman Islands-based drugmaker Danco Laboratories' Mifeprex (mifepristone), the abortifacient commonly referred to as RU-486, is unconstitutional, on the grounds that it is vague and endangers women's health, according to local media reports.
The Ohio legislation would restrict the use of Mifeprex to the Food and Drug Administration's guidelines of doeses of 600mg and only to be used in the first 49 days of gestation. The American College of Obstetricians and Gynecologists argued that the law criminalized and interfered with medical decisions that could be in the best interests of a woman's health.
US Senator Jim DeMint (Republican, South Carolina), is currently blocking the permanent appointment of Andrew von Eschenbach as FDA Commissioner, in protest at the availability of the drug in the USA (Marketletter September 25).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze